Substituted aromatic sulfonamides as antiglaucoma agents
CA 2022119 C · Owner: Merck & Co. Inc. · Inventors: Baldwin, John J.; Ponticello, Gerald S.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Carbonic anhydrase inhibitors of the thieno- 2,3-bthiopyran-2-sulfonamide type with a substitutedalkyl-amino group in the 4-position are topically effective in lowering intraocular pressure; the inhibitors are compounds of formula (I): wherein:, X is -S-, or -0-;, m is 0, 1 or 2 n is 0, 1 or 2, R is hydrogen or R1, R1 is 1) C2-7-alkene 2) C2-7-alkyne, 3) C1-5 alkyl having 1 2 or 3 substituents, wherein the substituents are independently:, a) halogen;, b) hydroxy; c) -NR6R7 wherein R6 and R7 are, independently: i) hydrogen, ii) C1-3 alkyl, iii) -CO-C1-3 alkyl or, iv) R6 and R7 taken together with the nitrogen to which they are, attached represent a saturated heterocycle of 5-7 members which, …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 27, 1990 and granted July 2, 2002. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended July 27, 2010.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 27, 2012.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.